The Life Sciences business grew 10 percent year over year, while the Diagnostics business inched up 1 percent.
An early user of a new Mycoplasma genitalium and antibiotic resistance test from SpeeDx that uses the Xpert cartridge shared some initial validation data.
The agency plans to evaluate newer RDTs in the future, and it is collaborating to bring molecular testing nearer to patients.
The study authors said that many cases of drug resistance remained undetected due to inaccurate tests, resulting in more deaths from incorrect treatment.
The firm's Life Sciences segment grew 10 percent year over year during the quarter while its Diagnostics segment was up 4 percent.
Researchers showed that the test had equivalent results to a lab-based assay and has the potential for a faster turnaround time.
The test measures hepatitis B viral DNA and is intended to be used to assess prognosis and response to antiviral therapies.
During the year, the growing threat of antimicrobial resistance drove development and adoption of advanced diagnostic tests, including molecular testing.
The company expects EPS to be between $4.02 and $4.12. On a non-GAAP basis, EPS is expected to be in the range of $4.75 and $4.85.
Developers of POC STI platforms and assays said that the tests provide convenience, privacy, and quick results in an area of testing in need of these benefits.